Abeona Therapeutics (NASDAQ:ABEO) had its target price decreased by Royal Bank of Canada to $16.00 in a research report sent to investors on Tuesday, The Fly reports. Royal Bank of Canada currently has a positive rating on the biopharmaceutical company’s stock. The analysts noted that the move was a valuation call.
A number of other research analysts have also recently weighed in on the stock. ValuEngine raised shares of Abeona Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. Mizuho cut shares of Abeona Therapeutics from a buy rating to a neutral rating and cut their price objective for the company from $17.00 to $4.00 in a report on Friday, July 26th. Maxim Group reaffirmed a buy rating on shares of Abeona Therapeutics in a report on Wednesday, May 1st. HC Wainwright began coverage on shares of Abeona Therapeutics in a report on Monday. They issued a buy rating and a $15.00 price objective for the company. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a sell rating to a hold rating in a report on Tuesday, July 30th. Six equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Abeona Therapeutics has an average rating of Hold and a consensus price target of $19.67.
Shares of Abeona Therapeutics stock opened at $2.17 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.54 and a quick ratio of 3.35. The firm has a fifty day moving average price of $3.54 and a 200 day moving average price of $6.08. Abeona Therapeutics has a 1 year low of $2.12 and a 1 year high of $15.65.
Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Friday, August 9th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.13). Abeona Therapeutics had a negative return on equity of 59.99% and a negative net margin of 960.91%. As a group, equities analysts expect that Abeona Therapeutics will post -1.74 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. BNP Paribas Arbitrage SA grew its position in shares of Abeona Therapeutics by 21,590.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 6,477 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Abeona Therapeutics by 434.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 7,088 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Abeona Therapeutics by 247.2% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,194 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 7,258 shares during the period. Ellington Management Group LLC acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $50,000. Finally, Trexquant Investment LP acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at about $53,000. 63.32% of the stock is owned by institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading: Guidelines for Successful Channel Trading
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.